AccurKardia vs Ceribell (2026)
Two cleared products that let a non specialist get a specialist answer, from different signals. AccurKardia interprets the electrocardiogram, device agnostic across sources, aimed at organisations holding more tracings than they can read. Ceribell brings its own instrument, a rapidly placed headband feeding a model that estimates seizure burden and flags suspected status epilepticus in departments where no neurologist is available. The economics differ as much as the clinical question: one runs on data you already collect and costs nothing per patient, the other requires hardware and a consumable but produces a signal that otherwise would not exist at all. Neither publishes subgroup performance, and the relevant subgroups differ by modality.
- It analyses the electrocardiogram itself, cleared Class II software producing near automated interpretation and deliberately device agnostic across ECG sources.
- The input is a tracing the organisation already captures, so the constraint addressed is interpretation capacity rather than data collection.
- For a service with volumes of slowly read tracings, that is the bottleneck and this is aimed at it.
- It brings its own instrument, a rapidly placed headband feeding a model that estimates seizure burden where no neurologist is standing by.
- A clear regulatory leader in its niche with a progression of clearances including age specific expansions.
- The algorithm's operation is described with unusual specificity, interpreting continuously across channels rather than producing a single classification.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. AccurKardia and Ceribell are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | AccurKardia | Ceribell |
|---|---|---|
| Primary category | Diagnostics & Genomics | Diagnostics & Genomics |
| Founded | 2019 | 2014 |
| Headquarters | New York, New York, United States | Sunnyvale, California, United States |
| Website | accurkardia.com | ceribell.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards AccurKardia its top capability grade on AI Centrality and FDA and Regulatory Status. Set against Ceribell, AccurKardia grades higher on EHR and Interoperability Depth. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Ceribell its top capability grade on AI Centrality and FDA and Regulatory Status. Set against AccurKardia, Ceribell grades higher on Security Certifications and Trust Center and Setting and Specialty Coverage. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose AccurKardia or Ceribell?
On the axes where the AI Health Index separates them, AccurKardia grades higher on EHR and Interoperability Depth, and Ceribell grades higher on Security Certifications and Trust Center and Setting and Specialty Coverage. Ceribell leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do AccurKardia and Ceribell differ most?
The widest separation the AI Health Index records between AccurKardia and Ceribell is on EHR and Interoperability Depth, where AccurKardia grades B and Ceribell grades C. That axis sits in the Integration and Deployment group, so it should carry the most weight for a buyer whose binding constraint is how the product lands in the stack already in place.
Where do AccurKardia and Ceribell grade the same?
The AI Health Index grades AccurKardia and Ceribell the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have AccurKardia and Ceribell not disclosed?
At the last review, at least one of AccurKardia and Ceribell published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
These read different signals for different questions and are compared because both are cleared point of care neuro and cardiac diagnostics that reach a decision without a specialist present. Neither publishes subgroup or population performance, and the questions differ by modality: electrocardiogram morphology varies with sex, age and body habitus, while electroencephalogram interpretation is affected by age and by sedation state. Neither publishes pricing, and for a device based product the consumable and instrument cost per patient materially changes the economics.